Peptide library / Sexual & reproductive / Lutetium Lu-177 vipivotide tetraxetan
Lutetium Lu-177 vipivotide tetraxetan
A radioactive targeted therapy for advanced prostate cancer.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- PSMA-positive metastatic castration-resistant prostate cancerFDA approved
How it is thought to work
A small peptide-like molecule binds PSMA on prostate cancer cells and delivers radiation directly to them.
What the evidence shows
The VISION trial showed longer survival when added to standard care.
Safety and unknowns
Fatigue, dry mouth, nausea and low blood counts.
Regulatory status
FDA-approved as Pluvicto in 2022.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Sexual & reproductive
Nafarelin
FDA-approvedA nasal-spray GnRH agonist for endometriosis and early puberty.
Oxytocin
FDA-approvedA nine amino acid hormone used to start labor and control bleeding after birth.
Kisspeptin-10
In clinical trialsA ten amino acid fragment of the hormone that switches on puberty and fertility.
General information, not medical advice. Do not buy or inject unregulated peptides.